Technical Data Sheet

PT-141

Also Known As: Bremelanotide, Vyleesi, PT 141, PT141, Melanocortin sexual peptide, MC4R agonist peptide, Libido peptide, Sexual arousal peptide, Cyclic lactam MSH analog, Melanocortin-4 receptor agonist, Hypoactive sexual desire peptide, HSDD treatment, Female sexual dysfunction peptide, Bremelanotide acetate, melanocortin agonist

Scan To View Profile

Evidence Tier	Approved Drug
Category	Sexual Health & Hormones
Class	Cyclic heptapeptide melanocortin receptor agonist; Melanotan II analog without linear structure
Molecular Target	MC4R (melanocortin-4 receptor) in hypothalamus; dopaminergic sexual arousal pathway; also MC1R (minor)
Sequence	Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH
Molecular Weight	~1025 Da
CAS	189691-06-3
Parent	alpha-MSH analog; melanotan II metabolite
Mechanism	It bypasses the vascular system entirely and binds to melanocortin receptors in the brain (MC3R and MC4R), directly stimulating the central nervous system pathways responsible for sexual arousal.
Studied For	Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA approved), Erectile dysfunction research (historical), Female sexual arousal disorder, Male sexual dysfunction research, Libido enhancement, Sexual arousal stimulation, Melanocortin system sexual research, Orgasmic dysfunction research, Pornography-induced erectile dysfunction models, Testosterone-independent sexual arousal, CNS-mediated sexual response, Female orgasm research, libido, erectile dysfunction, ED, female sexual arousal disorder, aphrodisiac, sexual dysfunction
Administration Route	Injection Only
Form	solution (autoinjector) or lyophilized
Diluent	bacteriostatic water
Storage Temperature	controlled room temp, dark; do not freeze
Light Sensitive	Yes
Freeze / Thaw	avoid
Reconstituted Shelf Life	30 Days
Handling Notes	Slows gastric emptying.
Regulatory	FDA-approved (Vyleesi, 2019) for premenopausal HSDD.
Sources